XML 33 R23.htm IDEA: XBRL DOCUMENT
v3.21.2

Share-Based Compensation | 9 Months Ended
--- | ---
Jul. 02, 2021
Share-based Payment Arrangement [Abstract] |
Share-based Payment Arrangement | SHARE-BASED COMPENSATION Stock Plans As of July 2, 2021, we had 6.0 million shares available for issuance under our 2021 Omnibus Incentive Plan (the “2021 Plan”), which replaced our 2012 Omnibus Incentive Plan (as amended and restated) (the “2012 Plan”), and 1.5 million shares available for issuance under our 2021 Employee Stock Purchase Plan (the “Employee Stock Purchase Plan”), which replaced our 2012 Employee Stock Purchase Plan. Under the 2021 Plan, we have the ability to issue incentive stock options (“ISOs”), non-statutory stock options (“NSOs”), stock appreciation rights (“SARs”), restricted stock awards (“RSAs”), unrestricted stock awards, stock units (including restricted stock units (“RSUs”) and performance-based restricted stock units (“PRSUs”)), performance awards, cash awards, and other share-based awards to employees, directors, consultants and advisors. The ISOs and NSOs must be granted at an exercise price, and the SARs must be granted at a base value, per share of not less than 100% of the closing price of a share of our common stock on the date of grant (or, if no closing price is reported on that date, the closing price on the immediately preceding date on which a closing price was reported) (110% in the case of certain ISOs). We have outstanding awards under the 2021 Plan, as well as the 2012 Plan. Following the adoption of the 2021 Plan, no additional awards have been or will be made under the 2012 Plan. Options granted under the 2012 Plan primarily vested based on certain market-based and performance-based criteria. Options granted generally have a term of four years to seven years. Certain of the share-based awards granted and outstanding as of July 2, 2021 are subject to accelerated vesting upon a change in control of the Company. Share-Based Compensation The following table shows a summary of share-based compensation expense included in the condensed consolidated statements of operations (in thousands):
| Three Months Ended |  | Nine Months Ended
| July 2, 2021 |  | July 3, 2020 |  | July 2, 2021 |  | July 3, 2020
Cost of revenue | $ | 777 |  |  | $ | 814 |  |  | $ | 2,482 |  |  | $ | 2,771 |
Research and development | 3,198 |  |  | 2,921 |  |  | 10,183 |  |  | 9,939 |
Selling, general and administrative | 4,166 |  |  | 4,760 |  |  | 14,176 |  |  | 14,211 |
Total share-based compensation expense | $ | 8,141 |  |  | $ | 8,495 |  |  | $ | 26,841 |  |  | $ | 26,921 |
As of July 2, 2021, the total unrecognized compensation costs related to RSAs, RSUs and PRSUs was $47.1 million, which we expect to recognize over a weighted-average period of 2.1 years. As of July 2, 2021, total unrecognized compensation cost related to our Employee Stock Purchase Plan was $0.8 million. Stock Options A summary of stock option activity for the nine months ended July 2, 2021 is as follows (in thousands, except per share amounts and contractual term):
| Number of Shares |  | Weighted-Average Exercise Price per Share |  | Weighted-Average Remaining Contractual Term (in Years) |  | Aggregate Intrinsic Value
Options outstanding as of October 2, 2020 | 325 |  |  | $ | 15.12 |  |  |  |  |
Exercised | (60) |  |  | 16.30 |  |  |  |  |
Forfeited, canceled or expired | — |  |  | — |  |  |  |  |
Options outstanding as of July 2, 2021 | 265 |  |  | $ | 14.85 |  |  | 6.73 |  | $ | 12,637 |
Options vested and exercisable as of July 2, 2021 | 265 |  |  | 14.85 |  |  | 6.73 |  | 12,637 |
Aggregate intrinsic value represents the difference between our closing stock price on July 2, 2021 and the exercise price of outstanding, in-the-money options. The total intrinsic value of options exercised was $0.4 million and $2.5 million for the three and nine months ended July 2, 2021, respectively, and was $0.7 million and $1.0 million for the three and nine months ended July 3, 2020, respectively. Restricted Stock, Restricted Stock Units and Performance-Based Restricted Stock Unit Awards A summary of stock award activity for the nine months ended July 2, 2021 is as follows:
| Number of shares (in thousands) |  | Weighted- Average Grant Date Fair Value
Balance as of October 2, 2020 | 2,788 |  |  | $ | 20.84 |
Granted | 958 |  |  | 30.97 |
Vested and released | (1,284) |  |  | 21.37 |
Forfeited, canceled or expired | (106) |  |  | 25.72 |
Balance as of July 2, 2021 | 2,356 |  |  | $ | 24.45 |
Stock awards that vested during the nine months ended July 2, 2021 and July 3, 2020 had combined fair values of $64.0 million and $18.7 million, respectively, as of the vesting date.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration